olmesartan

(redirected from Benicar)
Also found in: Medical.

ol·me·sar·tan

 (ŏl′mə-sär′tən)
n.
An angiotensin II receptor blocker drug, C24H26N6O3, used in the form of its medoxomil ester to treat hypertension.

[olme-, origin unknown + -sartan, angiotensin II receptor blocker suffix; see losartan.]
Translations

olmesartan

n olmesartán m
Mentioned in ?
References in periodicals archive ?
When pregnancy is detected, discontinue Benicar as soon as possible.
The treatment is made by Japanese firm Daiichi Sankyo and marketed as Benicar outside the UK.
9, 2015 /PRNewswire/ -- The number of claims filed against the makers of the hypertension medication Benicar (olmesartan medoxomil) have increased dramatically since the establishment of the multidistrict litigation (MDL).
Government, as well as participating states to conclude a Federal investigation related to certain types of speaker programs related to Azor, Benicar, Benicar HCT, Welchol and Tribenzor.
Information about some of the studies reviewed by the FDA, including a large observational study of Medicare patients, will be included in the labels of olmesartan products, which include Benicar, Benicar HCT, AZO, Tribenzor, and generics.
Daiichi Sankyo has started its business in Venezuela prior to the other Japanese pharmaceutical companies and has built its presence with innovative pharmaceuticals such as the hypertension medicine Benicar.
Tribenzor combines amlodipine, marketed by Pfizer as Norvasc, olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a third drug, hydrochlorothiazide.
Madonia prescribed various medications to treat Baggett, eventually settling on Benicar for her high blood pressure and Wellbutrin and Prozac for her depression.
Daiichi Sankyo, the maker of the Benicar hypertension medicine, is mimicking Novartis AG and Johnson & Johnson in diversifying as sales of branded products slow.
Sankyo and Daiichi Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Benicar (olmesartan medoxomil) and the synthetic antibacterial agent Cravit (levofloxacin).
Food and Drug Administration (FDA) for a fixed dose combination of two antihypertensives, the calcium channel blocker (CCB) amlodipine besylate (currently marketed by Pfizer as Norvasc) and the angiotensin receptor blocker (ARB) olmesartan medoxomil, or Benicar.
in Forreston, Illinois: Benicar and Synthroid should not worsen a person's glaucoma.